Hongcheng Biopharma

Hongcheng Biopharma, formally Shanghai Hongcheng Pharmaceutical, is a China-based innovative biopharma company focused on biologics and related oncology and immunology programs. The company was founded in 2020 as a wholly owned subsidiary of Beta Pharma and was built in Shanghai Zhangjiang as an R&D and manufacturing-oriented unit for innovative biologics and biosimilars. Its disclosed pipeline includes HC010, a trispecific antibody against PD-1, CTLA-4, and VEGF for advanced solid tumors; HC006, an anti-CCR8 monoclonal antibody in Phase 1; and HC022, a biologic in Phase 1 for systemic and cutaneous lupus erythematosus. External pipeline databases also indicate preclinical ADC work and a pembrolizumab biosimilar program. Overall, the company appears to be an early clinical-stage Chinese biotech centered on antibody-based therapeutics for oncology and autoimmune disease.